智通财经APP获悉，礼邦医药-B(09637)现涨超13%，截至发稿，涨10.75%，报28.24港元，成交额844.09万港元。
根据灼识咨询的资料，礼邦医药拥有全球肾脏适应症覆盖范围最广的候选药物。截至最后实际可行日期，公司的临床及临床前产品组合由一款核心产品AP301及六款其他候选产品组成，其中包括：一款临床后期候选产品(AP306)、一款临床前期候选药物(AP303)，以及四款临床前候选药物(AP308、AP304、AP305与AP307)。据悉，核心产品AP301已进入NDA冲刺阶段，距商业化落地仅12-24个月窗口。
值得注意的是，礼邦医药上一交易日(7月2日)股价出现“瀑布杀”，但剔除开盘竞价后，真正把股价砸到26港元下方的连续竞价卖单，合计不足24万股，只占全天827万股成交量的不到3%。在股价触及22.70港元后，资金在28-29港元区间进行了极其充分的筹码交换，形成较为坚实的共识底部。向前看，30元为短期阻力位，一旦放量突破并站稳，可以确认修复趋势成立。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.